Source-grounded facts extracted from Emmaus Life Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Emmaus Life Sciences, Inc. reported three months ended March 31, 2026 results: revenue $2.0 million, net income $3.3 million, EPS $0.05 basic net loss per share.
“Net revenues for the three months ended March 31, 2026 were $2.0 million, compared to $2.4 million in the same period in 2025.”
Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.
“Net revenues for the year ended December 31, 2025 were $12.5 million”
Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).
“n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence”
Emmaus Life Sciences, Inc. entered into License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. valued at an upfront payment (effective 2025-12-24).
“On December 24, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, entered into a License and Exclusive Distribution Agreement, or License Agreement, dated as of the same day pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory, in exchange for an upfront payment and a royalty on NIT’s Product sales.”
Emmaus Life Sciences, Inc. entered into Exchange Agreement and Exchange Note with a single individual valued at Issued 6,332,692 shares of common stock valued at approx. $0.38 per share and a convertible promisso (effective 2025-12-17).
“On December 17, 2025, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" and the "company") entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the "Exchange Shares") and a convertible promissory note in the principal amount of $600,000 (the "Exchange Note" and together with the Exchange Shares, the "Exchange Securities") in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the "Subject Note")”
Emmaus Life Sciences, Inc. issued convertible promissory note, principal $600,000 of convertible note to a single individual for surrender for cancellation of $3,000,000 convertible promissory note.
“On December 17, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the “Exchange Shares”) and a convertible promissory note in the principal amount of $600,000 (the “Exchange Note” and together with the Exchange Shares, the “Exchange Securities”) in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the “Subject Note”).”
Emmaus Life Sciences, Inc. issued 6,332,692 shares of common stock to a single individual for surrender for cancellation of $3,000,000 convertible promissory note.
“On December 17, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the “Exchange Shares”) and a convertible promissory note in the principal amount of $600,000 (the “Exchange Note” and together with the Exchange Shares, the “Exchange Securities”) in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the “Subject Note”).”
Emmaus Life Sciences, Inc. incurred convertible notes of $600,000 at 10% maturing due on demand.
“On December 17, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the “Exchange Shares”) and a convertible promissory note in the principal amount of $600,000 (the “Exchange Note” and together with the Exchange Shares, the “Exchange Securities”) in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the “Subject Note”). The Subject Note bore interest at the annual rate of 10%, payable semi-annually, and was convertible at the election of the holder into shares of our common stock at the conversion price of $0.13 per share. The Exchange Note will bear interest at the annual rate of 10%, payabl”
Emmaus Life Sciences, Inc. engaged CBIZ CPAs P.C. as its auditor.
“with the approval of the Audit Committee of our Board of Directors, CBIZ CPAs was engaged as our independent registered public accounting firm”
Marcum LLP resigned as auditor of Emmaus Life Sciences, Inc..
“Marcum resigned as the independent registered public accounting firm of Emmaus Life Sciences, Inc.”
Seah Lim resigned as director at Emmaus Life Sciences, Inc..
“On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.”
Emmaus Life Sciences, Inc. engaged Marcum LLP as its auditor.
“On October 22, 2024, the Audit Committee of the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) engaged Marcum LLP as our independent registered public accounting firm”
Jon Kuwahara was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..
“the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.”
George Sekulich was terminated as Chief Commercial Officer at Emmaus Life Sciences, Inc..
“in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024”
George Sekulich resigned as Director at Emmaus Life Sciences, Inc..
“On September 30, 2024, George Sekulich resigned as a member of the Board of Directors”
Willis Lee was appointed as Chief Executive Officer at Emmaus Life Sciences, Inc..
“On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.”
Emmaus Life Sciences, Inc. amended convertible notes of $9 million with note holders at 10% per annum, payable semi-annually maturing February 24, 2025.
“On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.”
Emmaus Life Sciences, Inc. entered into Exchange Agreement with note holders valued at $9 million principal amount of convertible promissory notes (effective 2024-02-21).
“On February 21, 2024, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) entered into an Exchange Agreement pursuant to which we agree to issue $9 million principal amount of convertible promissory notes of the company due February 24, 2025 (the “Exchange Notes”) in exchange for the surrender for cancellation and satisfaction in full of a like principal amount of our outstanding convertible promissory notes due February 24, 2024.”
Emmaus Life Sciences, Inc. reported the nine months ended September 30, 2023 results: net income net loss of $4.9 million, EPS $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.
“For the nine months ended September 30, 2023, the company reported a net loss of $4.9 million, or $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.”
Emmaus Life Sciences, Inc. reported the three months ended September 30, 2023 results: net income net income of $0.1 million, EPS $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha.
“For the quarter, the company realized net income of $0.1 million, or $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per share based on approximately 138.4 million weighted average diluted common shares.”
Emmaus Life Sciences, Inc. reported the three and nine months ended September 30, 2023 results: revenue $5.0 million and $22.5 million, respectively.
“Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.”
Willis Lee was appointed as Chairman of the Board of Directors at Emmaus Life Sciences, Inc..
“Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.”
Yutaka Niihara resigned as Director at Emmaus Life Sciences, Inc..
“Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.”
George Sekulich was appointed as interim Co-President at Emmaus Life Sciences, Inc..
“Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.”
Willis Lee was appointed as interim Co-President at Emmaus Life Sciences, Inc..
“Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.”
Emmaus Life Sciences, Inc. reported three and six months ended June 30, 2023 results: revenue $10.8 million and $17.5 million, net income net loss of $1.5 million, or $0.03 per share, EPS $0.03 per share.
“Net revenues for the three months and six months ended June 30, 2023 were $10.8 million and $17.5 million, respectively”
Emmaus Life Sciences, Inc. reported the three months ended March 31, 2023 results: revenue $6.8 million, net income net loss of $3.5 million, EPS $0.07 per share.
“Net Revenues. Net revenues for the three months ended March 31, 2023 were $6.8 million, compared to $3.2 million for same period in 2022. The increase was primarily attributable to increased sales both in the U.S. and the Middle East North Africa (MENA) region. Net revenues in Q1 2023 were positively affected by sales of Endari in the MENA region, including Kuwait, where Endari was approved for marketing in late 2022, as well as increased U.S. sales as inventory overstocking by distributors was resolved. Operating Expenses . Total operating expenses for the three months ended March 31, 2023 were $7.5 million, compared with $5.3 million for the same period in 2022. Of the increased expenses in Q1 2023, $1.2 million was attributable to an increase in share-based compensation and $0.9 million to an increase in selling expenses. Loss From Operations. Loss from operations for the three months ended March 31, 2023 was $1.2 million, compared to $3.1 million in the same period in 2022. The dec”
Emmaus Life Sciences, Inc. reported the year ended December 31, 2022 results: revenue $18.4 million, net income ($10.6 million, or $0.21 per share), EPS $(0.21) per share.
“earlier in 2022, so the sales momentum is strong for the upcoming year.” Financial and Operating Results Net Revenues. Net revenues for the year ended December 31, 2022 were $18.4 million, compared to $20.6 million for 2021. Although sales volume as measured by number of boxes of Endari sold increased compared to 2021, net revenues were adversely affected by”
Emmaus Life Sciences, Inc. shareholders approved To ratify the appointment of Baker Tilly US, LLP as independent registered public accounting firm at the 2022-12-08 meeting.
“Proposal 3: Votes For Votes Against Votes Withheld Broker Non-Votes To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 29,515,739 50,244 34,104 0”
Emmaus Life Sciences, Inc. shareholders approved To approve the amendment to our restated certificate of incorporation to authorize a reverse stock split at the 2022-12-08 meeting.
“Proposal 2: Votes For Votes Against Votes Withheld Broker Non-Votes To approve the amendment to our restated certificate of incorporation to authorize our Board of Directors in its discretion to effect a reverse stock split of the outstanding shares of our common stock within one year following the Annual Meeting at a ratio of not less than 1-for-5 nor greater than 1-for-8 28,880,074 679,945 40,068 0”
Emmaus Life Sciences, Inc. shareholders approved To elect the five nominees named below to our Board of Directors at the 2022-12-08 meeting.
“Proposal 1: To elect the five nominees named below to our Board of Directors, to serve until the next annual meeting of stockholders and until their successors are elected and qualified or their earlier retirement, resignation or removal: Votes For Votes Withheld Broker Non-Votes Yutaka Niihara, M.D., M.P.H. 23,176,995 400,562 6,022,530 Willis C. Lee 23,194,026 383,531 6,022,530 Seah Lim, M.D., Ph.D. 23,233,528 344,029 6,022,530 Wei Peu Derek Zen 23,229,478 348,079 6,022,530 Ian Zwicker 23,233,428 344,129 6,022,530”
Emmaus Life Sciences, Inc. reported nine months ended September 30, 2022 results: revenue $12.5 million, net income a net loss of $10.8 million, EPS $0.22 per share.
“this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order purchases in 2022”
Emmaus Life Sciences, Inc. reported three months ended September 30, 2022 results: revenue $4.9 million, net income a net loss of $0.4 million, EPS $0.01 per share.
“any transactions in this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order”
Seah H. Lim was appointed as Director at Emmaus Life Sciences, Inc..
“The Board also appointed Seah H. Lim, M.D., Ph.D. as a director to fill a vacancy on the five-person Board.”
Ian Zwicker was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..
“the Board appointed Ian Zwicker as a director of the company and as the Chair and sole member of the Audit Committee”
Masaharu Osato resigned as Member of the Board of Directors at Emmaus Life Sciences, Inc..
“On September 28, 2022, Dr. Masaharu Osato resigned as a member of the Board of Directors of Emmaus Life Sciences, Inc.”
Robert Dickey IV resigned as Director at Emmaus Life Sciences, Inc..
“By letter dated August 4, 2022, Robert Dickey IV resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) over a disagreement with management of the company.”
Jane Pine Wood resigned as Director at Emmaus Life Sciences, Inc..
“By letter dated June 8, 2022, Lori Teranishi, Alfred Lui, M.D., and Jane Pine Wood graciously tendered their resignation as directors of Emmaus Life Sciences, Inc.”
Alfred Lui resigned as Director at Emmaus Life Sciences, Inc..
“By letter dated June 8, 2022, Lori Teranishi, Alfred Lui, M.D., and Jane Pine Wood graciously tendered their resignation as directors of Emmaus Life Sciences, Inc.”
Lori Teranishi resigned as Director at Emmaus Life Sciences, Inc..
“By letter dated June 8, 2022, Lori Teranishi, Alfred Lui, M.D., and Jane Pine Wood graciously tendered their resignation as directors of Emmaus Life Sciences, Inc.”
Lori Teranishi was appointed as director at Emmaus Life Sciences, Inc..
“expanded the number of directors from seven to eight and appointed Lori Teranishi as a director of the company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.